8 Well-Funded Stem Cell Startups are Manipulating your DNA

Follow StartuptoEnterprise.com on Google News

Stem Cell Startups

Using stem cells or their derivatives, stem cell startups champion the production of regenerative medicine, also known as stem cell therapy, to promote the repair response of diseased, dysfunctional, or injured tissue. Instead of using donor organs in short supply, stem cells are used for stem cell therapy.

In the laboratory, researchers cultivate stem cells to manipulate them into specific cell types like those found in the heart, blood, or nerve tissue, such as heart muscle cells. The manipulated cells are then injected directly into the target muscle with the degenerative condition to usher in new cell development.

With the advancement in stem cell technology, several medical researchers, doctors, and scientists have established stem cell startups making an innovative impact globally, often breakthrough and promising for the future of fatal diseases, including but not limited to cancer or degenerative muscle atrophy.

So, if the question is if you approve these stem cell startups from South Korea, the UK, US, India, Switzerland, Japan, Germany, and France manipulate your DNA? You are likely to respond positively after learning about their impact!


Stem Cell Startups: South Korea, UK, the US, India, Switzerland, Japan, Germany, France

Medipost- South Korea

Founded in 2000, Medipost is spearheaded by the CEO & President, Dr. Yoon-Sun Yang. Medipost is a stem cell startup based in Seongnam, Kyonggi-do, South Korea. There is no public information about its funding or investors. Medipost helps patients with incurable diseases unraveling unmet medical needs through stem cells and regenerative medicine. South Korea-based Medipost has been resilient in stem cell research and commercialization while upholding strong corporate ethics and values. The firm holds the world’s first regulatory-approved allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cell(hUCB-MSC) product named CARTISTEM® for patients with knee osteoarthritis(OA), launched in the Korean market in 2012.

Locate Bio- United Kingdom

Founded in 2001, Locate Bio was founded by Kevin Shakesheff. Locate Bio is a stem cell startup based in Beeston, Nottinghamshire, United Kingdom. The UK-based stem cell startup has raised $22.4M in funding so far from five investors. The biotechnology startup focuses on regenerative medicine development, such as orthobiologics. Locate Bio exists to help surgeons improve the lives of people with debilitating spinal conditions. The experts at Locate Bio are always pursuing high-value opportunities with clear unmet clinical needs in stem cell science with a firm grounding in robust scientific evidence. 

LifeCell International- India

Founded in 2004 by Mayur Abhaya, LifeCell International is a stem cell startup based in Chennai, Tamil Nadu, India. The stem cell startup has raised $41.1M in funding so far from three investors. The startup is a private stem cell bank that brings the concept of umbilical cord stem cell banking to India. The firm has become a comprehensive stem cells solutions provider with a complete spectrum of services, including multi-service stem cell banking, R&D, stem cell clinical trials, and stem cell therapy. It has a spread over 100 service centers in India and the GCC countries.

Antion Biosciences- Switzerland

Founded in 2016, Antion Biosciences is spearheaded by the CEO & President, Sven Kili. Antion Biosciences SA is a stem cell startup based in Geneva, Geneve, Switzerland. There is no public information about its funding or investors. This Swiss cell and gene engineering company develops highly innovative allogeneic therapies to cure diseases with significant unmet medical needs through ground-breaking cell engineering. The approved chimeric antigen receptor (CAR) T-cell therapies in the market are costly, time-consuming, logistically challenging and fraught with manufacturing failures, which deters scaling up the manufacturing. With Antion’s innovative allogeneic molecular therapies such as miCARTM T-cells manufactured from healthy donor cells, faulty genes are silenced and disease state altered successfully.


Metcela- Japan

Founded in 2016 by Kenichi Nogami, Takahiro Iwamiya, Metcela Inc. is a stem cell startup based in Kawasaki, Kanagawa, Japan. The stem cell startup has raised $21.4M in funding so far from fifteen investors. Metcela stem cell startup is a clinical-stage biotech startup providing patients with an alternative treatment option for heart disease. The company’s lead asset, MTC001, is a cell therapy based on VCAM-1-positive Cardiac Fibroblast (VCF) that re-established a favorable microenvironment and repaired damaged heart tissues in preclinical studies. Metcela’s therapy uses a specific fibroblast cell obtained from the patient’s heart. Instead of replacing them, it repairs the damage by enhancing the cells’ ability to heal, providing patients with an effective and reasonably-priced cure for heart failure.

PAN-Biotech GmbH – Germany

Founded in 2017 by Nabiha Saklayen, Cellino Biotech is a stem cell startup based in Cambridge, Massachusetts, United States. The stem cell startup has raised $17.5M in funding so far from five investors. Cellino Biotech startup develops intracellular delivery lasers and nanotechnology for gene editing applications like iPS (induced pluripotent stem cell) therapy producing pancreatic islet cells. The company makes stem cell differentiation a digital process, applying the latest tools from optics, biology, and computation to engineer functionally mature cells. Its technology enables the acceleration of the development time of engineered cells from years to weeks.

TreeFrog Therapeutics- France

Founded in 2018 by Jean-Luc Treillou, TreeFrog Therapeutics is a stem cell startup based in Bordeaux, Aquitaine, France. The stem cell startup has raised $86.9M in funding so far from 10 investors. The startup secures quality cell production, fastens clinical development, and facilitates market access. The company’s offerings include a proprietary technology platform that provides an end-to-end 3D scalable solution that will dramatically reduce treatment costs, enabling patients to access the medical revolution of cell therapies by overcoming current critical manufacturing issues.

Garuda Therapeutics – the United States

Founded in 2021, Garuda Therapeutics was founded by Harvard Professor Dr. Dhvanit Shah, Dr. Sean Morrison, and Dr. David Scadden. Garuda Therapeutics is the newest of all disruptive stem cell startups based in Natick, Massachusetts, United States. The US-based stem cell startup has raised $72M in funding so far from nine investors. The life sciences firm focuses on generating off-the-shelf, self-renewing blood stem cells is designed to provide patients with rapid and broad access to consistent, durable, HLA-matched transgene-free blood stem cell therapies. According to a statement from the company, Garuda is developing the world’s first off-the-shelf hematopoietic stem cell platform that will eliminate dependency on donor or patient cells.


Dear Reader, 

First, thank you for your precious time reading the stories (without paywalls) I publish on Startups to Enterprises covering the EUChinathe US, and India. Second, I request you to contribute financially (any amount) to help me sustain this as an independent digital business news media. 

If I receive a request for a sponsored post, I ensure I see merit that is meaningful for erudite and informed readers like you. In the bargain, I lose out on sponsorships wherein I need funds to sustain this effort. Your contribution helps me stay afloat.

Please note that your contribution is treated as revenue generated and not a donation; hence, there are no 80G or other donation certificates. In fact, as I am eligible to pay for the revenue generated, I will pay taxes on the same.

You deserve to know that I abide by journalistic ethics and practices to ensure I tell the stories as is, unbiased. You can follow us on FacebookLinkedin, and Twitter, bookmark us on Google News, and finallyPayPal us here.

Founding Editor

Linda Ashok  
Skip to content